Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Bone Marrow Transplant ; 26(4): 413-7, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10982288

RESUMEN

The incidence, treatment and outcome of CMV interstitial pneumonia (CMV-IP) were reviewed in 139 consecutive allogeneic BMT patients undergoing extended CMV antigenemia surveillance and two different ganciclovir (GCV) strategies to control CMV infection. Nineteen cases of CMV-IP were reviewed, 16 of 63 patients (25.4%) who received early GCV treatment (ET) and three of 76 patients (3.9%) who received preemptive (PE) GCV therapy. In the ET group, the median time for occurrence of CMV-IP was 55 (range 36 to 311) days. Two patients had three episodes of CMV-IP recurrences after day +100. CMV-IP-related death occurred in two patients (15.4%). In the PE group, 41 patients received pre-emptive GCV therapy prompted by the appearance of positive antigenemia > or =2 cells. The median time for the occurrence of CMV-IP was 92 (range 48 to 197) days. Response to therapy was observed when GCV was introduced within 6 days of antigenemia positivity. The use of IVIg in association with GCV did not play a major role in response to therapy. The median time for occurrence of CMV-IP was delayed during PE strategy and the cost-effectiveness of CMV surveillance after day +100 should be investigated in this population.


Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Infecciones por Citomegalovirus/tratamiento farmacológico , Ganciclovir/administración & dosificación , Neumonía Viral/tratamiento farmacológico , Adolescente , Adulto , Antígenos Virales/metabolismo , Antivirales/administración & dosificación , Antivirales/normas , Niño , Preescolar , Infecciones por Citomegalovirus/epidemiología , Infecciones por Citomegalovirus/inmunología , Quimioterapia Combinada , Ganciclovir/normas , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Inmunoglobulinas Intravenosas/normas , Incidencia , Enfermedades Pulmonares Intersticiales/tratamiento farmacológico , Enfermedades Pulmonares Intersticiales/epidemiología , Enfermedades Pulmonares Intersticiales/virología , Persona de Mediana Edad , Neumonía Viral/epidemiología , Premedicación , Estudios Retrospectivos , Tasa de Supervivencia , Trasplante Homólogo/efectos adversos , Resultado del Tratamiento
2.
Rev Inst Med Trop Sao Paulo ; 43(3): 163-6, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11452326

RESUMEN

We report a case of cutaneous infection caused by Phialemonium curvatum GAMS et COOKE, 1983, after bone marrow transplantation. The genus Phialemonium was created by GAMS & MCGINNIS in 1983 including three new species: Ph. obovatum, Ph. curvatum and Ph. dimorphosporum, and represents an intermediate genus between Acremonium and Phialophora. Nowadays, the genus Phialemonium is considered to be a pheoid fungus which may cause the eventual lesions observed in pheo- and hyalohyphomycosis. Species of this genus have been described as opportunistic agents in humans and animals, mainly as a result of immunosuppression. In the present case, the patient had multiple myeloma and received an allogenic bone marrow transplant from his HLA-compatible brother. Two months after transplantation, he developed purplish and painful nodular lesions on the right ankle. Some of these lesions drained spontaneously and apparently hyaline mycelial filaments were observed, whose culture was initially identified as Acremonium sp. Subsequent studies showed that the fungus was Phialemonium curvatum. The infection was treated with amphotericin B, followed by ketoconazole. The patient was submitted to surgical debridement followed by two skin grafts to repair the bloody area. The duration of the treatment was 4 months and secondary prophylaxis with ketoconazole alone was maintained for one additional month. No recurrence was observed after discontinuation of treatment. The authors comment on the pathogenicity of the genus Phialemonium.


Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Dermatomicosis/microbiología , Hongos Mitospóricos/aislamiento & purificación , Infecciones Oportunistas/complicaciones , Adulto , Dermatomicosis/tratamiento farmacológico , Humanos , Huésped Inmunocomprometido , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA